上海交通大学学报（医学版）

上海交通大学学报（医学版） ›› 2018, Vol. 38 ›› Issue (4): 394-.doi: 10.3969/j.issn.1674-8115.2018.04.007

• 论著·基础研究 • 上一篇    下一篇

核糖体蛋白16高表达于前列腺癌并促进肿瘤进展

潘玉龙1，齐隽2，周亮1，张彤彤1，李强1   

  1. 1. 四川省成都市第三人民医院泌尿外科，成都 610031；2. 上海交通大学医学院附属新华医院泌尿外科，上海200092
  • 出版日期:2018-04-28 发布日期:2018-05-03
  • 通讯作者: 齐隽，电子信箱：asonqi@sh163.net。
  • 作者简介:潘玉龙（1984—），男，硕士生；电子信箱：yulong112358@163.com。
  • 基金资助:
    成都市科技局2013惠民工程项目（F01-36）

Ribosomal protein 16 overexpresses in prostate cancer and promotes tumor progression

PAN Yu-long1, QI Jun2, ZHOU Liang1, ZHANG Tong-tong1, LI Qiang1   

  1. 1. Department of Urology , The Third Peoples Hospital of Chengdu, Chengdu 610031, China; 2. Department of Urology , Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2018-04-28 Published:2018-05-03
  • Supported by:
    2013 Huimin Project of Chengdu Science and Technology Bureau, F01-36

PDF (PC)

1078

摘要： 目的·探讨核糖体蛋白16（ribosomal protein 16，RPS16）在前列腺癌发生发展中的作用。方法·运用Western blotting（WB）方法检测RPS16蛋白在25例前列腺癌组织和33例前列腺增生组织中的表达差异；免疫组织化学法（immunohistochemistry，IHC）检测RPS16蛋白在48例各期前列腺癌组织和42例良性对照组织中的表达差异。分析RPS16蛋白水平与患者临床指标的相关性。应用脂质体法将合成的RPS16小干扰RNA（siRNA）瞬时转染前列腺癌DU145及LNCaP细胞，实验组分为RPS16-siRNA1、RPS16siRNA2和RPS16-siRNA3，随机干扰RPS16-siRNA-NC为阴性对照组，未转染为空白对照组。转染后48～72 h进行WB检测判断RNA干扰效率。选择干扰最佳的实验组行后续细胞增殖实验、流式细胞术和transwell实验；判断干扰RPS16基因表达对前列腺癌DU145及LNCaP细胞增殖、细胞周期及细胞侵袭能力的影响。结果· WB证实RPS16蛋白在前列腺癌组织中的表达均高于对应的良性组织（P0.008）；IHC检测发现RPS16蛋白在前列腺癌和良性组织中染色强度差异明显（P0.009）。RPS16蛋白表达和患者年龄、是否转移无相关性，与肿瘤临床分期(P0.044)、病理分级(P0.004)显著相关。RPS16-siRNA不仅能显著降低前列腺癌DU145及LNCaP细胞RPS16蛋白水平，并且能明显抑制其细胞增殖和侵袭；细胞周期停滞在G2/M期。结论· RPS16蛋白表达上调能增强前列腺癌细胞的增殖和侵袭能力。

关键词: 核糖体蛋白16, 前列腺癌, RNA干扰, 侵袭, 增殖

Abstract:

Objective · To investigate the effects of ribosomal protein 16 (RPS16) on tumorigenesis and development of prostate cancer. Methods · Western blotting (WB) was used to detect the differences of RPS16 levels in 25 cases of prostate cancer tissues and 33 prostate hyperplasia, and immunohistochemistry (IHC) was performed to detect RPS16 levels in 48 prostate cancer tissues and 42 benign tissues. The relationship betweenRPS16 level and clinical pathological parameters of the patients was analyzed. The RPS16 small interfering RNA (siRNA) was transiently transfected into DU145 and LNCaP cellsliposome method, including RPS16-siRNA1, RPS16-siRNA2 and RPS16-siRNA3. Random disturbance RPS16-siRNA-NC was used as negative control, cells without transfection were blank control. The efficiency of RNA interference was detectedWB 48-72 h after transfection. RPS16-siRNA with highest efficiency was chosen for subsequent cell proliferation assay, flow cytometry (FCM) and transwell assay into detect the effects of RPS16 on cell proliferation, cell cycle and invasion ability of DU145 and LNCaP cells. Results · WB results showed that the level of RPS16 protein in the tissues of prostate cancer was higher than that of the benign group (P0.008). IHC results showed RPS16 protein level was significantly higher in tumor tissues than benign tissues (P0.009). RPS16 was not correlated with age and metastasis, but significantly correlated with clinical stage (P0.044) and pathological grade of the tumor (P0.004). RPS16 siRNA can not only significantly reduce the ofRPS16 protein in DU145 and LNCaP cells, but also inhibit the proliferation and invasion of the cancer cells, so that the cell cycle arrested in G2/M phase. Conclusion · The high of RPS16 protein could enhance the proliferation and invasive ability of prostate cancer cells.

Key words: ribosomal protein 16, prostate cancer, RNA interference , invasion, proliferation

中图分类号: